These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 21590790)

  • 41. Incorporating lower grade toxicity information into dose finding designs.
    Iasonos A; Zohar S; O'Quigley J
    Clin Trials; 2011 Aug; 8(4):370-9. PubMed ID: 21835856
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase I study of continuous MKC-1 in patients with advanced or metastatic solid malignancies using the modified Time-to-Event Continual Reassessment Method (TITE-CRM) dose escalation design.
    Tevaarwerk A; Wilding G; Eickhoff J; Chappell R; Sidor C; Arnott J; Bailey H; Schelman W; Liu G
    Invest New Drugs; 2012 Jun; 30(3):1039-45. PubMed ID: 21225315
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Estimating the dose-toxicity curve in completed phase I studies.
    Iasonos A; Ostrovnaya I
    Stat Med; 2011 Jul; 30(17):2117-29. PubMed ID: 21341302
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Quasi-partial order continual reassessment method: Applying toxicity scores to cancer dose-finding drug combination trials.
    O'Connell NS; Wages NA; Garrett-Mayer E
    Contemp Clin Trials; 2023 Feb; 125():107050. PubMed ID: 36529437
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A default method to specify skeletons for Bayesian model averaging continual reassessment method for phase I clinical trials.
    Pan H; Yuan Y
    Stat Med; 2017 Jan; 36(2):266-279. PubMed ID: 26991076
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The impact of non-drug-related toxicities on the estimation of the maximum tolerated dose in phase I trials.
    Iasonos A; Gounder M; Spriggs DR; Gerecitano JF; Hyman DM; Zohar S; O'Quigley J
    Clin Cancer Res; 2012 Oct; 18(19):5179-87. PubMed ID: 22825582
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Practical modifications of the continual reassessment method for phase I cancer clinical trials.
    Faries D
    J Biopharm Stat; 1994 Jul; 4(2):147-64. PubMed ID: 7951271
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The 3 + 3 design in dose-finding studies with small sample sizes: Pitfalls and possible remedies.
    Chiuzan C; Dehbi HM
    Clin Trials; 2024 Jun; 21(3):350-357. PubMed ID: 38618916
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The rapid enrollment design for Phase I clinical trials.
    Ivanova A; Wang Y; Foster MC
    Stat Med; 2016 Jul; 35(15):2516-24. PubMed ID: 26833922
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Surv-CRM-12: A Bayesian phase I/II survival CRM for right-censored toxicity endpoints with competing disease progression.
    Andrillon A; Chevret S; Lee SM; Biard L
    Stat Med; 2022 Dec; 41(29):5753-5766. PubMed ID: 36259523
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase I dose-escalation oncology trials with sequential multiple schedules.
    Günhan BK; Weber S; Seroutou A; Friede T
    BMC Med Res Methodol; 2021 Apr; 21(1):69. PubMed ID: 33853539
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Continual reassessment method for dose escalation clinical trials in oncology: a comparison of prior skeleton approaches using AZD3514 data.
    James GD; Symeonides SN; Marshall J; Young J; Clack G
    BMC Cancer; 2016 Aug; 16(1):703. PubMed ID: 27581751
    [TBL] [Abstract][Full Text] [Related]  

  • 53. TITE-BOIN-ET: Time-to-event Bayesian optimal interval design to accelerate dose-finding based on both efficacy and toxicity outcomes.
    Takeda K; Morita S; Taguri M
    Pharm Stat; 2020 May; 19(3):335-349. PubMed ID: 31829517
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Performance of two-stage continual reassessment method relative to an optimal benchmark.
    Wages NA; Conaway MR; O'Quigley J
    Clin Trials; 2013; 10(6):862-75. PubMed ID: 24085776
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Towards using a full spectrum of early clinical trial data: a retrospective analysis to compare potential longitudinal categorical models for molecular targeted therapies in oncology.
    Colin P; Micallef S; Delattre M; Mancini P; Parent E
    Stat Med; 2015 Sep; 34(22):2999-3016. PubMed ID: 26059319
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Optimal phase I dose-escalation trial designs in oncology--a simulation study.
    Gerke O; Siedentop H
    Stat Med; 2008 Nov; 27(26):5329-44. PubMed ID: 17849502
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Adaptive prior variance calibration in the Bayesian continual reassessment method.
    Zhang J; Braun TM; Taylor JM
    Stat Med; 2013 Jun; 32(13):2221-34. PubMed ID: 22987660
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A novel toxicity scoring system treating toxicity response as a quasi-continuous variable in Phase I clinical trials.
    Chen Z; Krailo MD; Azen SP; Tighiouart M
    Contemp Clin Trials; 2010 Sep; 31(5):473-82. PubMed ID: 20609419
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Continual reassessment method with regularization in phase I clinical trials.
    Li X; Ivanova A; Tian H; Lim P; Liu K
    J Biopharm Stat; 2020 Nov; 30(6):964-978. PubMed ID: 32926652
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of irrational dose assignment definitions using the continual reassessment method.
    Wages NA; Bagley E
    Clin Trials; 2019 Dec; 16(6):665-672. PubMed ID: 31547691
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.